2 cases of therapy-related acute myeloid leukemia (t-AML) after treatment of rhabdmyosarcoma(RMS)
演題番号 : PS-1-41
中川 夏季 （Natsuki Nakagawa):1、橋井 佳子 （Yoshiko Hashii):1、吉田 寿雄 （Hisao Yoshida):1、宮下 恵実子 （Emiko Miyashita):1、宮村 能子 （Takako Miyamura):1、大薗 恵一 （Keiichi Ozono):1
1:developmental medicine Osaka University graduate school of medicine, Japan
Although the prognosis of malignancies have improved, secondary malignancies has increased in the past 20 years. Secondary malignancies are the most devastating late effects of cancer therapy, because they tend to be refractory to treatment, have many complications.
We report 2 cases of t-AML after treatment of RMS.
He was diagnosed stage 3 RMS at three years old. Chemotherapy, radiotherapy, and an operation were undergone and it resulted in remission. Six months after the end of treatment, at the age of seven, he was diagnosed AML. He received chemotherapy, and allogenic stem cell transplantation (SCT) from father (HLA 2 locus mismatch). There was no complications expect acute GVHD grade 3. There is no recurrence for 4 months.
She was diagnosed stage 3 RMS at three years old. Chemotherapy, radiotherapy, and an operation were undergone and it resulted in remission. Six months after the end of treatment, at the age of four, she was diagnosed AML. She received chemotherapy, and allogenic SCT from mother (HLA 3 locus mismatch). She was suffered from acute GVHD grade 2. The side effects (>grade 3) were mucosal injury and liver dysfunction. There is no recurrence for twelve years.
The most effective treatment of t-AML is allogenic SCT, but there are many complications. Our two cases have resulted in remission with standard chemotherapy, and were undergone SCT at an early stage.
A good prognosis was suggested by gaining remission with the safe and effective chemotherapy to intractable t-AML and performing SCT at an early stage.